0001213900-20-028696.txt : 20200928 0001213900-20-028696.hdr.sgml : 20200928 20200928170416 ACCESSION NUMBER: 0001213900-20-028696 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200928 DATE AS OF CHANGE: 20200928 EFFECTIVENESS DATE: 20200928 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AYTU BIOSCIENCE, INC CENTRAL INDEX KEY: 0001385818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 470883144 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38247 FILM NUMBER: 201205210 BUSINESS ADDRESS: STREET 1: 373 INVERNESS PARKWAY STREET 2: SUITE 206 CITY: ENGLEWOOD STATE: CO ZIP: 80112 BUSINESS PHONE: (720) 437-6580 MAIL ADDRESS: STREET 1: 373 INVERNESS PARKWAY STREET 2: SUITE 206 CITY: ENGLEWOOD STATE: CO ZIP: 80112 FORMER COMPANY: FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC. DATE OF NAME CHANGE: 20150609 FORMER COMPANY: FORMER CONFORMED NAME: Rosewind CORP DATE OF NAME CHANGE: 20070110 NT 10-K 1 ea127484-nt10k_aytubio.htm NT 10-K

 

 

 

  UNITED STATES  
  SECURITIES AND EXCHANGE COMMISSION  
  Washington, D.C.  20549  
   
     
  FORM 12b-25  
     
   
  NOTIFICATION OF LATE FILING  
     
   

 

 

(Check One): ☒ Form 10-K   ☐ Form 20-F  ☐ Form 11-K  ☐ Form 10-Q  ☐ Form 10-D  ☐ Form N-CEN

                       ☐ Form N-CSR

 

For Period Ended: June 30, 2020            

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

  For the Transition Period Ended:  

  

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

 

PART I -- REGISTRANT INFORMATION

 

Aytu BioScience, Inc.

Full Name of Registrant

 

 

Former Name if Applicable

 

373 Inverness Parkway, Suite 206

Address of Principal Executive Office (Street and Number)

 

Englewood, CO 80112

City, State and Zip Code

 

 

 

 

 

 

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

  (a)    The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

☒

 (b)    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
  (c)    The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

Aytu BioScience, Inc. (the “Company”) is filing this Form 12b-25 with the Securities and Exchange Commission (the “Commission”) to postpone the filing of its Annual Report on Form 10-K for the annual period ended June 30, 2020 (the “Form 10-K”) beyond September 28, 2020, the prescribed due date for such filing. The postponement allows for additional time to finalize financial statements due to the additional workload created by the recently completed acquisition of Innovus Pharmaceuticals (the "Innovus Merger") and the Cerecor, Inc. pediatric prescription portfolio (the "Pediatric Portfolio") and to accommodate scheduling needs related to COVID-19. The Company expects to file the Form 10-K with the Commission no later than fifteen calendar days after the original prescribed date, as permitted by Rule 12b-25.

PART IV — OTHER INFORMATION

(1)Name and telephone number of person to contact in regard to this notification

 

  David A. Green   (720)   437-6580
  (Name)   (Area Code)   (Telephone Number)

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s)

☒ Yes   ☐ No

 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

☒ Yes   ☐ No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

Explanation of Significant Changes in Results of Operations. The Company’s results of operations for the year-ended June 30, 2020 includes 8 months of financial results relating to its acquisition of the Pediatric Portfolio on November 1, 2020 and approximately 4.5 months of financial results relating to the February 14, 2020 Innovus Merger.

 

 

Aytu BioScience, Inc.
(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: September 28, 2020   By /s/ David A. Green